Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
- 5 April 2017
- journal article
- research article
- Published by Elsevier BV in The Lancet Respiratory Medicine
- Vol. 5 (5), 390-400
- https://doi.org/10.1016/s2213-2600(17)30125-x
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysisRespiratory Research, 2013
- Clinimetrics corner: a closer look at the minimal clinically important difference (MCID)Journal of Manual & Manipulative Therapy, 2012
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012
- Methods for interpreting change over time in patient-reported outcome measuresQuality of Life Research, 2012
- Dyspnea perception in asthma: Role of airways inflammation, age and emotional statusRespiratory Medicine, 2011
- An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and ExacerbationsAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Cluster Analysis and Clinical Asthma PhenotypesAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Asthma: defining of the persistent adult phenotypesThe Lancet, 2006
- Impaired Perception of Dyspnea in Patients with Severe AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 1998
- A Self-complete Measure of Health Status for Chronic Airflow Limitation: The St. George's Respiratory QuestionnaireAmerican Review of Respiratory Disease, 1992